Vertex Pharmaceuticals Revenue decreased by 6.4% to $2.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $2.77B to $2.99B. Over 4 years (FY 2021 to FY 2025), Revenue shows an upward trend with a 12.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growth in market share or higher demand, while a decrease may signal market saturation or competitive pressure.
Represents the total consideration received from customers for the sale of goods or services, excluding any sales-relate...
Standard across all public companies; comparable to 'Net Sales' or 'Total Revenue' at peer distributors.
other_revenue_from_contract_with_customer_excluding_asse_0d5b70| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.79B | $1.98B | $2.07B | $2.10B | $2.20B | $2.33B | $2.30B | $2.37B | $2.49B | $2.48B | $2.52B | $2.69B | $2.65B | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
| QoQ Change | — | +10.6% | +4.5% | +1.2% | +4.7% | +6.3% | -1.4% | +3.1% | +5.0% | -0.4% | +1.4% | +6.9% | -1.7% | +4.8% | +5.1% | -4.9% | +7.0% | +3.8% | +3.7% | -6.4% |
| YoY Change | — | — | — | — | +22.5% | +17.7% | +11.1% | +13.2% | +13.5% | +6.4% | +9.3% | +13.3% | +6.1% | +11.6% | +15.7% | +3.0% | +12.1% | +11.0% | +9.5% | +7.8% |